Advertisement
GH vs NTRA
Which Stock Would AI Choose? Guardant Health (GH) vs. Natera (NTRA) Stock Comparison
Key Takeaways
- Guardant Health (GH) delivered strong second-quarter 2026 results with 44% revenue growth and raised full-year guidance, driving recent stock momentum.
- Natera (NTRA) continues to benefit from expanding clinical adoption of its Signatera platform, supported by multiple analyst upgrades and regulatory milestones in recent months.
- Both companies operate in precision diagnostics but differ in scale, with Natera generating substantially higher revenue and demonstrating path toward quarterly profitability.
- GH stock has outperformed on a year-to-date basis amid screening test adoption, while NTRA shows more balanced long-term returns and diversified test volumes.
- Sector exposure centers on oncology and genetic testing, with both facing reimbursement and competition risks in a high-growth but volatile healthcare environment.
- Relative positioning favors stability for one and catalyst-driven upside for the other based on observable trend and financial metrics.
Introduction
Guardant Health (GH) and Natera (NTRA) represent two prominent players in the precision diagnostics space, offering investors exposure to oncology testing and genetic analysis amid advancing personalized medicine. This comparison examines their business models, recent market performance, and relative positioning for traders and investors seeking to understand contrasts in growth trajectories, risk profiles, and sentiment within the healthcare sector. The analysis draws on verifiable developments from recent market activity to provide context for portfolio decisions without forward-looking speculation.
GH Overview and Recent Performance
Guardant Health (GH) specializes in precision oncology, with its Shield blood-based screening test and oncology assays driving revenue. In recent weeks, the company reported second-quarter 2026 results showing 44.3% year-over-year revenue growth to $335 million, alongside raised full-year guidance. This performance contributed to positive sentiment, with the stock closing at approximately $161.99 on July 31 after a 6.33% single-day gain. Broader market activity reflects strong year-to-date returns of about 58.6%, supported by increasing test volumes and reimbursement progress in screening. Factors influencing performance include clinical adoption of Shield and overall sector interest in non-invasive diagnostics.
NTRA Overview and Recent Performance
Natera (NTRA) focuses on genetic testing through platforms such as Signatera for minimal residual disease detection and other women's health and transplant applications. Recent market activity highlights continued volume growth and clinical data releases, with multiple analyst price target increases and regulatory updates including IVDR certification. As of the July 31 close, shares traded near $267.76 amid typical volatility, with year-to-date performance around 9.7% to 16.9% depending on the measurement window. Sentiment has been supported by expanding partnerships and study publications, though the company awaits its second-quarter 2026 earnings report scheduled for early August. Performance reflects a more established revenue base compared with peers in the diagnostics field.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the most suitable AI trading bots from hundreds available that trade thousands of different tickers. Only those demonstrating strong alignment with current market conditions earn placement in this section. Available bots span diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics ranging across various risk levels and return profiles. This selection process highlights options suited to different investor preferences while maintaining a neutral, informational focus. Traders seeking automated strategies can explore the full range on the Trending AI Robots page.
Head-to-Head Comparison
Guardant Health (GH) and Natera (NTRA) both target oncology and diagnostics but differ in scale and maturity. Natera maintains substantially larger revenue, exceeding $2 billion annually, with a broader test portfolio that supports more diversified cash flows. Guardant Health (GH) emphasizes its Shield screening platform, which has shown accelerated adoption recently. Momentum contrasts appear in recent price behavior, with Guardant Health (GH) exhibiting sharper post-earnings gains while Natera (NTRA) displays steadier long-term appreciation. Risk factors include reimbursement dependencies for both, though Natera (NTRA) has progressed toward positive cash flow in certain periods. Sector exposure remains similar within healthcare innovation, yet market sentiment tilts toward stability for the larger player and catalyst sensitivity for the growth-oriented one.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative financial stability, and catalyst positioning, Tickeron’s AI analysis would currently lean toward favoring Natera (NTRA) with moderate probability. The company’s scale, diversified revenue streams, and recent regulatory progress contribute to a more balanced profile in the current environment. Guardant Health (GH) presents higher-beta characteristics tied to screening momentum that could appeal under specific algorithmic signals. This assessment remains probabilistic and derived solely from historical patterns and reported metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GH is a StrongBuy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GH’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- GH’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GH’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- GH’s TA Score: 4 bullish, 2 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
GH (@Medical Specialties) experienced а +1.18% price change this week, while NTRA (@Medical Specialties) price change was +15.07% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.62%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was +24.12%.
Reported Earning Dates
GH is expected to report earnings on Oct 29, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (+0.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| GH | NTRA | GH / NTRA | |
| Capitalization | 21.4B | 44.8B | 48% |
| EBITDA | -411.19M | -227.7M | 181% |
| Gain YTD | 61.651 | 37.920 | 163% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 1.18B | 2.5B | 47% |
| Total Cash | 1.05B | 1.09B | 97% |
| Total Debt | 1.7B | 240M | 707% |
GH | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 65 Fair valued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 74 | 22 | |
SMR RATING 1..100 | 100 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NTRA's Valuation (49) in the Biotechnology industry is in the same range as GH (65) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is somewhat better than the same rating for GH (74) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew somewhat faster than GH’s over the last 12 months.
NTRA's SMR Rating (96) in the Biotechnology industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that NTRA’s stock grew similarly to GH’s over the last 12 months.
GH's Price Growth Rating (35) in the Medical Or Nursing Services industry is in the same range as NTRA (36) in the Biotechnology industry. This means that GH’s stock grew similarly to NTRA’s over the last 12 months.
GH's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as NTRA (100) in the Biotechnology industry. This means that GH’s stock grew similarly to NTRA’s over the last 12 months.
| GH | NTRA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 81% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Advances ODDS (%) | 9 days ago 82% | 10 days ago 80% |
| Declines ODDS (%) | 3 days ago 85% | 3 days ago 77% |
| BollingerBands ODDS (%) | N/A | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 80% |
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.04% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.01% | ||
| GH - NTRA | 50% Loosely correlated | +0.01% | ||
| ADPT - NTRA | 50% Loosely correlated | -0.55% | ||
| MTD - NTRA | 47% Loosely correlated | +0.09% | ||
| GKOS - NTRA | 47% Loosely correlated | +2.54% | ||
More | ||||